Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $44,000.00 in Stock

by · The Markets Daily

Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) Director Jeri Williams sold 110 shares of Axon Enterprise stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the sale, the director now directly owns 1,934 shares in the company, valued at approximately $773,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Axon Enterprise Stock Performance

Shares of AXON opened at $415.05 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The stock has a market cap of $31.32 billion, a P/E ratio of 121.36, a PEG ratio of 10.59 and a beta of 0.94. The company has a 50-day moving average of $361.35 and a two-hundred day moving average of $322.04. Axon Enterprise, Inc. has a 12-month low of $190.01 and a 12-month high of $415.11.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.80 earnings per share. As a group, research analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dorsey Wright & Associates grew its holdings in shares of Axon Enterprise by 0.3% during the second quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 39 shares in the last quarter. Avantax Advisory Services Inc. grew its holdings in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after buying an additional 40 shares in the last quarter. Brookstone Capital Management grew its holdings in shares of Axon Enterprise by 5.1% during the first quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock worth $263,000 after buying an additional 41 shares in the last quarter. CWM LLC grew its holdings in Axon Enterprise by 1.5% in the second quarter. CWM LLC now owns 2,820 shares of the biotechnology company’s stock valued at $830,000 after purchasing an additional 43 shares during the period. Finally, Wealthspan Partners LLC grew its holdings in Axon Enterprise by 4.9% in the second quarter. Wealthspan Partners LLC now owns 965 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 45 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on AXON. Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 target price on the stock. Craig Hallum lifted their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. JMP Securities raised their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective for the company. Finally, Barclays raised their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

Check Out Our Latest Research Report on Axon Enterprise

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

See Also